A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Adva
A phase 1/2 trial of T3011, Pembrolizumab in melanoma, run by ImmVira Pharma Co. Ltd, now recruiting.
Overview
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT04370587 by ImmVira Pharma Co. Ltd, with 30 participants planned, started 2020-09-17 and due to reach its primary completion in 2026-09-22. Interventions recorded: T3011, T3011 + pembrolizumab. Conditions listed: Solid Tumor, Melanoma, HNSCC, Sarcoma. No results are recorded here; the registry entry is the source.
Setting
A Phase 1/2a, Open-Label, Dose Escalation and Expansion Study of the Safety and Tolerability of T3011 Administered Via Intratumoral Injection as a Single Agent and in Combination With Intravenous Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
Phase
Phase 1/2
Sponsor
ImmVira Pharma Co. Ltd
Registry
Enrolled
30